Nigel Ramsden

Currently EVP of Chemistry at RxCelerate with responsibility for design and execution of small molecule drug discovery programs for clients from screening to clinical proof of concept. In addition I manage the bioanalytical group and act as TFM for the GxP studies performed and manage GMP manufacture of APIs. RxCelerate is as an outsourced drug development platform specializing in bespoke experimental design with data-rich end-points. We can drive your asset through drug discovery, medicinal chemistry, preclinical research and beyond; maximizing your chances of reaching the clinic. RxCelerate offers comprehensive investigation packages and stand-alone assays with in-built flexibility, making it the perfect partner for both virtual, asset-centric companies and large pharmaceutical companies seeking to outsource elements of their project. We combine client consultation with in-house expertise to ensure that our in vitro design and preclinical models are robust and information rich, improving both compound progression and translational capacity. Choosing RxCelerate as your business partner will add financial and intellectual benefits to your drug candidate, helping to move it through IND within an accelerated time frame

RxChemistry is part of the Rxcelerate Out-Sourced Drug Development Platform. Together with RxBiology and Rx&D we bring innovative thinking (the brains) as well as delivery (the hands) in chemistry, biology and integration to your programs. Just provide the target. We will deliver the drug.

Director Head of Operations Vice President of Medicinal Chemistry SYNthesis is a contract research organisation providing synthetic and medicinal chemistry services. The company was established in 2007 and operates a unique, “best of both worlds” business model combining Western medicinal chemistry expertise with a cost effective and scalable synthetic chemistry capacity based in China.

Autophagix is a small, entrepreneurial biotech company dedicated to the discovery, design and progression of novel therapeutics for autophagy modulation and the treatment of inflammatory disorders. Autophagy is an essential homeostatic process by which cells degrade their own proteins and organelles and is important in balancing the benefical and detrimental effects of immunity and inflammation. Dysregulation of autophagy has been implicated in a wide range of disorders including IBD, SLE and various neurodegenerative conditions. Autophagix was formed as a spin-out from Cellzome following its acquisition by GSK in 2012.

Responsible for building a portfolio of targets and small molecules for the treatment of Alzheimer's Disease, partnering this portfolio with J&J and co-chairing the resulting steering committee. Co-invented Cellzome's Kinobeads and Episphere technologies and optimised their use to support drug discovery programs in inflammation, resulting in the purchase of Cellzome by GSK

Built Cellzome's medicinal and synthetic capabilities